Sign In
Buy NAVB
$0.0001
+0 (+0%)
At Close: Dec 30, 2025
Navidea Biopharmaceuticals, Inc. Files for Bankruptcy
04:57pm, Wednesday, 08'th Oct 2025
COLUMBUS, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (“Navidea” or the “Company”), a biopharmaceutical company focused on the development of precision immunodiagnostic agents and
Navidea Biopharmaceuticals, Inc. Announces Extension of Authority to Implement a Reverse Stock Split
02:52pm, Wednesday, 21'st May 2025
COLUMBUS, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (OTC: NAVB) (“Navidea” or the “Company”), a biopharmaceutical company focused on the development of precision immunodiagnostic
Navidea Biopharmaceuticals Announces the Extension of Plan Designed to Protect NOLs and Other Tax Assets
06:08pm, Monday, 31'st Mar 2025
COLUMBUS, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (“Navidea” or the “Company”) today announced that its Board of Directors has elected to extend the Company's Section 382 Right
Navidea Biopharmaceuticals, Inc. Announces Results of Exploratory Analysis Completed on July 2, 2024
04:30pm, Wednesday, 03'rd Jul 2024
COLUMBUS, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (OTC: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immuno
Navidea Biopharmaceuticals, Inc. announces special meeting of stockholders to be held July 8, 2024
06:02pm, Thursday, 20'th Jun 2024
COLUMBUS, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (OTC: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immuno
Navidea Biopharmaceuticals, Inc. Files Form 15 to Voluntarily Deregister and Suspend its SEC Reporting Obligations
07:05pm, Friday, 26'th Jan 2024
COLUMBUS, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. Files Form 15 to Voluntarily Deregister and Suspend its SEC Reporting Obligations.
Navidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. Enter Binding Settlement Agreement and Mutual Release
08:30am, Friday, 01'st Dec 2023
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. Enter Binding Settlement Agreement and Mutual Release.
Navidea Biopharmaceuticals, Inc. Announces NYSE American's Decision to Suspend Trading In Its Common Stock
09:01pm, Thursday, 05'th Oct 2023
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. Announces NYSE American's Decision to Suspend Trading In Its Common Stock.
NYSE American to Suspend Trading in Navidea Biopharmaceuticals, Inc. (NAVB)
04:19pm, Thursday, 05'th Oct 2023
NEW YORK--(BUSINESS WIRE)--NYSE American LLC (“NYSE American” or the “Exchange”) announced today that the staff of NYSE Regulation has determined to suspend trading in the common stock of Navi
Navidea Biopharmaceuticals, Inc. NAVB Requests Oral Hearing With NYSE Hearing Panel
09:29am, Thursday, 10'th Aug 2023
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. NAVB Requests Oral Hearing With NYSE Hearing Panel.
Navidea Biopharmaceuticals, Inc. Presses Ahead, Embraces Opportunities
09:32am, Monday, 31'st Jul 2023
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. Presses Ahead, Embraces Opportunities.
Why Is Navidea Biopharmaceutical (NAVB) Stock Down 13% Today?
09:08am, Monday, 31'st Jul 2023
Navidea Biopharmaceutical (NYSEMKT: NAVB ) stock is falling on Monday after the biopharmaceutical company got a major delisting warning. The NYSE American LLC sent the company a notice about its fail
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American Determination.
NYSE American to Commence Delisting Proceedings Against Navidea Biopharmaceuticals, Inc. (NAVB)
04:18pm, Friday, 28'th Jul 2023
NEW YORK--(BUSINESS WIRE)--NYSE American LLC (“NYSE American” or the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the common s
Navidea Biopharmaceuticals, Inc. Hires Craig A. Dais, CPA as Chief Financial Officer
05:20pm, Thursday, 27'th Jul 2023
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. Hires Craig A. Dais, CPA as Chief Financial Officer.
